Do the new PCPT findings make you less likely to recommend finasteride for PCa?

Share this article:

After 18 months of follow-up of patients in the Prostate Cancer Prevention Trial (PCPT), Ian M. Thompson, Jr. MD, and colleagues found that finasteride decreased the risk of prostate cancer (PCa) by about a one third, but it had no effect on overall survival or survival after the diagnosis of PCa, according to a report in the New England Journal of Medicine (2013;369:603-610). 

In an editorial accompanying the report, Michael LeFevre, MD, wrote that the safest conclusion one can draw about the use of finasteride for PCa prevention “is that it has no short- or long-term effect on all-cause mortality, so we cannot recommend its use to prolong life.” 

Renal & Urology News invites urologists to answer the following online poll question.

Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

Have you ever stopped accepting private insurance that reimburses poorly?

Doctors may be at a big disadvantage when negotiating payment rates with private insurers.

What do you think of the penalties assessed against drug companies accused ...

Pharmaceutical companies have paid billions of dollars to settle federal allegations of fraud and other wrongdoing in recent years.

Do doctors have a moral duty to serve as expert witnesses in ...

Thousands of medical malpractice suits are filed in courts across the U.S. each year.